Jefferies Group's position in Protagonist Therapeutics is currently worth $35.9 Million. That's 0.57% of their equity portfolio (23rd largest holding). The investor owns 2.16% of the outstanding Protagonist Therapeutics stock. The first Protagonist Therapeutics trade was made in Q4 2022. Since then Jefferies Group bought shares three more times and sold shares on one occasions. The stake costed the investor $28.1 Million, netting the investor a gain of 28% so far.